Stroke outcome in clinical trial patients deriving from different countries

Stroke

Volumn 40, Issue 1, 2009, Pages 35-40

  Ali, Myzoon ^a,h   Atula, Sari ^a   Bath, Philip M W ^b   Grotta, James ^c   Hacke, Werner ^d   Lyden, Patrick ^e   Marler, John R ^f   Sacco, Ralph L ^g   Lees, Kennedy R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h Gardiner Institute   (United Kingdom)

Author keywords

Acute care; Clinical trials; Database; Epidemiology; Outcomes

Indexed keywords

ADULT; AGED; ANAMNESIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; AGE DISTRIBUTION; CANADA; CLINICAL TRIAL; DISABILITY; EUROPE; HEALTH; HOSPITALIZATION; INCIDENCE; META ANALYSIS; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; STATISTICS; STROKE; TIME; UNITED STATES;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CANADA; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; EUROPE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WORLD HEALTH;

EID: 60549106053     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.518035     Document Type: Article

References (43)

1. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas A, Schroll M, for the WHO MONICA Project. Stroke incidence, case fatality, and mortality in the WHO MONICA Project. Stroke. 1995;26:361-367.
2. Stegmayr B, Harmsen P, Rajakangas A, Rastenyté D, Sarti C, Thor-valdsen P, Tuomilehto J. Stroke around the Baltic Sea: incidence, case fatality and population risk factors in Denmark, Finland, Sweden and Lithuania. Cerebrovasc Dis. 1996;6:80-88.
3. Wolfe CD, Tilling K, Beech R, Rudd AG. Variations in case fatality and dependency from stroke in western and central Europe. The European BIOMED Study of Stroke Care Group. Stroke. 1999;30:350-356.
4. Thom TJ, Epstein FH, Feldman JJ, Leaverton PE, Wolz M. Total mortality and mortality from heart disease, cancer, and stroke from 1950 to 1987 in 27 countries: highlights of trends and their interrelationships among causes of death. Bethesda, MD: National Institutes of Health; 1992:NIH Publication No. 92-3088.
5. Gordon T. Mortality experience among the Japanese in the United States, Hawaii, and Japan. Public Health Report. 1957;72:543-553.
6. Wong KS, Haung YN, Gao S, Lam WWM, Chan YL. Cerebrovascular disease among Chinese populations-recent epidemiological and neuro-imaging studies. Hong Kong Med J. 2001;7:50-57.
7. Stegmayr B, Vinogradova T, Malyutina S, Peltonen M, Nikitin Y, Asplund K. Widening gap of stroke between east and west - eight-year trends in occurrence and risk factors in Russia and Sweden. Stroke. 2000;31:2-8.
8. Asplund K. Stroke in Europe: widening gap between East and West. Cerebrovasc Dis. 1996;6:3-6.
9. WHO MONICA Project. Stroke trends in the WHO MONICA Project. Stroke. 1997;28:500-506.
10. WHO MONICA Project. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA project. Stroke. 1997;28: 1367-1374.
11. Wolfe CDA, Giroud M, Kolominsky-Rabas P, Dundas R, Lemesle M, Heuschmann P, Rudd A, for the European Registries of Stroke Collaboration. Variations in stroke incidence and survival in 3 areas of Europe. Stroke. 2000;31:2074-2079.
12. Asplund K, Ashburner S, Cargill K, Hux M, Lees KR, Drummond M, for the GAIN International Investigators. Health care resource use and stroke outcome. Inte J Tech Assess Health Care. 2003;19:267-277.
13. Rudd AG, Irwin P, Rutledge Z. The national sentinel audit for stroke: a tool for raising standards of care. J Roy Coll Physicians Lond. 1999;33:464.
14. Langhorne P, Dennis M, ed. Stroke units: An evidence based approach. London: BMJ Books; 1998.
15. Asplund K, Rajakangas A-M, Kuulasmaa K. Multinational comparison of diagnostic procedures and management of acute stroke. The WHO MONICA Study. Cerebrovasc Dis. 1996;6:66-74.
16. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database System Rev. 2007;Issue 4:CD000197 (DOI: 10.1002/14651858.CD000197.pub2).
17. Gray LJ, Sprigg N, Bath PM, Sørensen P, Lindenstrøm E, Boysen G, De Deyn PP, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Ringelstein B, van der Sande JJ, Turpie AGG, for the TAIST Investigators. Significant variation in mortality and functional outcome after acute ischaemic stroke between western countries: Data from the tinzaparin in acute ischaemic stroke trial (TAIST). J Neurol Neurosurg Psychiatry. 2006;77:327-333.
18. Ali M, Bath PMW, Curram J, Davis SM, Diener HC, Donnan GA, Fisher M, Gregson BA, Grotta J, Hacke W, Hennerici M, Hommel M, Kaste M, Marler JR, Sacco RL, Teal P, Wahlgren NG, Warach S, Weir CJ, Lees KR. The Virtual International Stroke Trials Archive (VISTA). Stroke. 2007;38:1905-1910.
19. Sudlow CLM, Warlow CP. Comparable Studies of the Incidence of Stroke and its Pathological Types: Results from an International Collaboration. Stroke. 1997;28:491-499.
20. Kleindorfer D. The bad news: stroke incidence is stable. Lancet Neurol. 2007;6:470-471.
21. Kurth T, Berger K. The socio-economical stroke puzzle. Stroke. 2007; 38:4-5.
22. Marler J, for The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581-1587.
23. Kaste M, Boysen G, Indredavik B, Norrving B. Stroke unit care in Scandinavian countries. Int J Stroke. 2005;1:44.
24. Candelise L, Bersano A. Stroke units in Italy. Neurol Sci. 2006;27: S223-S224.
25. Beech R, Ratcliffe M, Tilling K, Wolfe C, on behalf of the participants of the European Study of Stroke. Hospital services for stroke care. Stroke. 1996;27:1958-1964. .
26. The World Health Organization. World Health Report 2006. Annex Table 3. 2006:187-189. Available at: http://www.who.int/whr/2006/ whr06-en.pdf. Accessed March 29, 2008.
27. The World Health Organization. World Health Report 2006. Annex Table 4. 2006:191-199 Available at: http://www.who.int/whr/2006/ whr06-en.pdf. Accessed March 29, 2008.
28. Cox AM, McKevitt C, Rudd AG, Wolfe CD. Socioeconomic status and stroke. Lancet Neurol. 2006;5:181-188.
29. Wolfe CDA, Rudd AG, Howard R, Coshall C, Stewart J, Lawrence E, Hajat C, Hillen T. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry. 2002;72:211-216.
30. Avendano M, Kawachi I, Van Lenthe F, Boshuizen HC, Mackenbach JP, Van den Bos GA, Fay ME, Berkman LF. Socioeconomic status and stroke incidence in the US elderly: the role of risk factors in the EPESE study. Stroke. 2006;37:1368-1373.
31. Van den Bos GA, Smits JP, Westert GP, van Straten A. Socioeconomic variations in the course of stroke: unequal health outcomes, equal care? J Epidemiol Community Health. 2002;56:943-948.
32. Markus H. Variations in care and outcome in the first year after stroke: a Western and Central European Perspective: large differences in outcome and resource utilisation. J Neurol Neurosurg Psychiatry. 2004;75: 1660-1661.
33. Sacco RL, Boden- Albala B, Gan R, Chen X, Kargman DE, Shea S. Stroke incidence among white, black and Hispanic residents of an urban community. The Northern Manhattan Stroke Study. Am J Epidemiology. 1998;147:259-268.
34. Sacco RL, Hauser W, Mohr J. Hospitalised stroke in blacks and Hispanics in northern Manhattan. Stroke. 1991;22:1491-1496.
35. Kittner S, White L, Losoncszy K, Wolf P, Hebel R. Black-white differences in stroke incidence in a national sample: the contribution of hypertension and diabetes mellitus. JAMA. 1990;264:1267-1270.
36. Hankey GJ. Clinical update: Management of stroke. Lancet. 2007;369: 1330-1332.
37. Holland WW. European Community Atlas of Avoidable Death, Ed. II. Oxford, UK: Oxford University Press; 1991.
38. Grieve R, Hutton J, Bhalla A, Rastenyte D, Ryglewicz D, Sarti C, Lamassa M, Giroud M, Dundas R, Wolfe CDA. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke. 2001;32:1684-1691.
39. Weir NU, Sandercock PA, Lewis SC, Signorini DF, Warlow CP. Variations between countries in outcome after stroke in the International Stroke Trial (IST). Stroke. 2001;32:1370-1377.
40. Grotta J, for the US and Canadian Lubeluzole stroke study group. Lubeluzole treatment for acute ischaemic stroke. Stroke. 1997;28:2338 -2346.
41. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T, on behalf of the LUB-INT-13 Investigators. Lubeluzole in Acute Ischaemic Stroke Treatment: A double -blind study with an 8 hour inclusion window comparing a 10mg daily dose of Lubeluzole with placebo. Stroke. 2000;31:2543-2551.
42. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischaemic stroke. N Engl J Med. 2006;354:588-600.
43. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U, for the SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.